Journal of Clinical and Translational Hepatology

Journal of Clinical and Translational Hepatology

Monday, 03 / 08 / 2021

Articles

REVIEW ARTICLE

An Update on Efficacy and Safety of Emerging Hepatic Antifibrotic Agents

Vinka Rupcic Rubin#,1, Kristina Bojanic*,2,3,4, Martina Smolic5,6Jurica Rubin7Ashraf Tabll8,9 and Robert Smolic*,7,10,11

1  Department of Gynaecology and Obstetrics, Osijek University Hospital Centre, Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia
2  Department of Biophysics and Radiology, Faculty of Dental Medicine and Health Osijek, J. J. Strossmayer University of Osijek, Osijek, Croatia
3  Department of Biophysics and Radiology, Faculty of Medicine Osijek, J. J. Strossmayer University of Osijek, Osijek, Croatia
4  Department of Radiology, Health Center Osijek, Osijek, Croatia
5  Department of Pharmacology and Biochemistry, Faculty of Dental Medicine and Health Osijek, J. J. Strossmayer University of Osijek, Osijek, Croatia
6  Department of Pharmacology, Faculty of Medicine Osijek, J. J. Strossmayer University of Osijek, Osijek, Croatia
7  Department of Medicine, Division of Gastroenterology/Hepatology, University Hospital Osijek, Osijek, Croatia
8  Microbial Biotechnology Department, Genetic Engineering and Biotechnology Research Division, National Research Centre, Dokki, Egypt
9  Department of immunology, Egypt Center for Research and Regenerative       Medicine (ECRRM), Cairo, Egypt
10  Department of Pathophysiology, Physiology and Immunology, Faculty of Dental Medicine and Health Osijek, J. J. Strossmayer University of Osijek, Osijek, Croatia
11  Department of Pathophysiology, Faculty of Medicine Osijek, J. J. Strossmayer University of Osijek, Osijek, Croatia
#  These authors contributed equally to this work.
*Correspondence to: Robert Smolic, J. J. Strossmayer University of Osijek Faculty of Medicine Osijek, Department of Pathophysiology J. Huttlera 4, Osijek 31000, Croatia. Tel: +385-31-512-800, Fax: +385-31-512-833, E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal of Clinical and Translational Hepatology 2021;9(1):60-70 DOI: 10.14218/JCTH.2020.00040
Received: May 3, 2020 Accepted: December 9, 2020 Published online: January 4, 2021

Abstract

Liver fibrosis represents a response to chronic liver injury. Metabolic dysfunction-associated fatty liver disease and metabolic dysfunction-associated steatohepatitis are the most common chronic liver diseases, both with increasing incidence. Therefore, there is a great impetus for development of agents targeting these conditions. Accumulating data on possible treatment options for liver fibrosis are emerging in the literature. However, despite extensive research and much effort in the field, approved agents for liver fibrosis are still lacking. In this critical review, we have summarized the main data about specific treatment options for liver fibrosis gained from ongoing clinical trials, with an emphasis on efficacy and safety of these agents.

Keywords

Liver fibrosis, MAFLD, MASH, Clinical trials, Antifibrotic agents, Efficacy, Safety

Journal of Clinical and Translational Hepatology 2021 vol. 9, 60-70  [ Html  ] [ PDF Full-text ]

© The Author(s) 2021. This article is published under the terms of the Creative Commons Attribution-Noncommercial License (CC BY-NC 4.0), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

 logo

You are here: Home